Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia

Novartis84 enrolled

Overview

The purpose of the study is to assess the safety and efficacy of fluvastatin in children diagnosed with heterozygous familial hypercholesterolemia

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Heterozygous Familial Hypercholesterolemia Mixed Dyslipidemia

Interventions

FluvastatinDRUG

Eligibility

Sex: ALLMin age: 10 YearsMax age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 10-16 years old Heterozygous familial hypercholesterolemia Exclusion Criteria: * Homozygous familial hypercholesterolemia Pregnant or lactating females Major surgery during the six month prior study Other protocol defined inclusion and exclusion criteria may apply

Locations (1)

Novartis

Basel, Switzerland

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.